ALGS

Business Context and Reporting Period

Company: Aligos Therapeutics, Inc. (ALGS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Aligos is a clinical-stage biotechnology company developing novel therapeutics for liver diseases (chronic hepatitis B virus, MASH) and viral infections (coronaviruses). The company has no products approved for commercial sale and has incurred significant losses since inception. It is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: Revenue consists of collaboration revenue ($0 in Q3 2025) and customer revenue ($741k in Q3 2025). The 9M 2025 Net Loss was significantly lower than 9M 2024 due to a $58.97 million gain from the change in fair value of 2023 common warrants.

Material Changes vs. Prior Period

• Revenue Decline: Revenue from customers decreased by 41% in Q3 2025 compared to Q3 2024 ($741k vs. $1.25m), attributed to the near completion of the original Amoytop agreement and the start of a lower-value extension.
• Operating Expenses: Total operating expenses increased 36% in Q3 2025 ($29.1m vs. $21.4m). Research and Development (R&D) expenses rose 43% ($23.9m vs. $16.8m), driven by the initiation of the Phase 2a clinical trial for pevifoscorvir sodium and a $9.0 million milestone payment to Emory University.
• Warrant Liability Impact: The company recorded a $4.2 million loss in Q3 2025 related to the change in fair value of 2023 common warrants, contrasting with a $59.0 million gain in the same period of 2024. This volatility significantly impacts the reported Net Loss.
• Liquidity Position: Cash, cash equivalents, and short-term investments increased to $99.1 million as of September 30, 2025, up from $56.9 million at year-end 2024, following a $105.0 million gross proceeds PIPE offering in February 2025.

Guidance, Outlook, and Risks

• Going Concern: Management states that current cash resources are sufficient to fund operations into the third quarter of 2026. This timeline is less than 12 months from the filing date, raising substantial doubt about the company's ability to continue as a going concern without additional financing.
• Clinical Pipeline Updates:
  • Pevifoscorvir sodium (HBV): Phase 2 B-SUPREME study is enrolling; first subject dosed in August 2025. Topline data anticipated in 2027.
  • ALG-055009 (MASH/Obesity): Phase 2a HERALD study met primary endpoint with significant liver fat reduction. Company is evaluating out-licensing options.
  • ALG-097558 (Coronavirus): Phase 2 AGILE trial ongoing; development partially funded by NIH/NIAID grants.
• Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional financing to achieve its goals. Failure to secure capital could force delays or termination of product development.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, reliance on third-party manufacturers, and potential intellectual property disputes.

Investor Verification Checklist

• Cash Runway: Verify the specific burn rate and confirm the timeline for funding operations into Q3 2026, given the "substantial doubt" disclosure.
• Warrant Liability Volatility: Assess the impact of the 2023 common warrants on future earnings, as fair value changes can cause significant fluctuations in Net Loss unrelated to operations.
• Revenue Sustainability: Confirm the status of the Amoytop agreement extension and the likelihood of future collaboration revenue, as current revenue streams are declining.
• Clinical Milestones: Monitor enrollment progress and safety data for the Phase 2 B-SUPREME study (pevifoscorvir sodium) and the AGILE trial (ALG-097558).
• Financing Plans: Review upcoming disclosures regarding the company's strategy to raise additional capital before the Q3 2026 liquidity horizon.